InMed Pharmaceuticals Inc
INM1.730USD
-0.120-6.49%
終値 11/04, 16:00（ET）15分遅れの株価
3.46M時価総額
損失額直近12ヶ月PER
詳細情報 InMed Pharmaceuticals Inc 企業名
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals Incの企業情報
企業コードINM
会社名InMed Pharmaceuticals Inc
上場日Jun 21, 2001
最高経営責任者「CEO」Mr. Eric A. Adams
従業員数- -
証券種類Ordinary Share
決算期末Jun 21
本社所在地1445-885 West Georgia St.
都市VANCOUVER
証券取引所National Stock Exchange of India
国Canada
郵便番号V6C 3E8
電話番号16046697207
ウェブサイトhttps://www.inmedpharma.com/
企業コードINM
上場日Jun 21, 2001
最高経営責任者「CEO」Mr. Eric A. Adams
InMed Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Director
Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Director
Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Thu, Oct 2
更新時刻: Thu, Oct 2
株主統計
種類
株主統計
株主統計
比率
Yorkville Advisors Global, LP.
3.37%
Sabby Management, LLC
1.52%
UBS Financial Services, Inc.
0.33%
Adams (Eric Ashley)
0.09%
Hull (Andrew Harold)
0.08%
他の
94.62%
株主統計
株主統計
比率
Yorkville Advisors Global, LP.
3.37%
Sabby Management, LLC
1.52%
UBS Financial Services, Inc.
0.33%
Adams (Eric Ashley)
0.09%
Hull (Andrew Harold)
0.08%
他の
94.62%
種類
株主統計
比率
Investment Advisor/Hedge Fund
4.89%
Investment Advisor
0.33%
Individual Investor
0.17%
Hedge Fund
0.02%
Research Firm
0.01%
他の
94.59%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
29
124.98K
5.24%
+38.52K
2025Q2
37
127.03K
6.34%
+18.71K
2025Q1
34
127.03K
10.75%
+32.44K
2024Q4
33
169.52K
14.04%
+76.54K
2024Q3
35
65.17K
63.92%
+11.73K
2024Q2
34
30.10K
7.60%
-6.51K
2024Q1
33
42.40K
13.49%
-1.13K
2023Q4
31
40.41K
15.37%
-91.29K
2023Q3
32
1.59K
1.33%
-12.58K
2023Q2
37
1.04K
0.99%
-13.60K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Yorkville Advisors Global, LP.
80.37K
3.37%
+80.37K
--
Dec 13, 2024
Sabby Management, LLC
36.13K
1.52%
+20.77K
+135.22%
Dec 31, 2024
UBS Financial Services, Inc.
7.76K
0.33%
+1.66K
+27.12%
Jun 30, 2025
Adams (Eric Ashley)
2.20K
0.09%
-5.70K
-72.17%
Jun 30, 2025
Hull (Andrew Harold)
1.91K
0.08%
-425.00
-18.19%
Jun 30, 2025
Tower Research Capital LLC
400.00
0.02%
+400.00
--
Jun 30, 2025
SBI Securities Co., Ltd.
300.00
0.01%
--
--
Jun 30, 2025
Banque Cantonale Vaudoise
6.00
0%
--
--
Jun 30, 2025
Hsu (Eric Chih-Hsien)
2.00
0%
-1.95K
-99.90%
Jun 30, 2025
Bessemer Trust Company, N.A. (US)
1.00
0%
+1.00
--
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sun, Nov 2
更新時刻: Sun, Nov 2
銘柄名
比率
AdvisorShares Pure Cannabis ETF
0%
AdvisorShares Pure Cannabis ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
日付
種類
比率
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
